An open-label, randomized, controlled, multicenter study exploring two treatment strategies of rivaroxaban and a dose-adjusted oral vitamin k antagonist treatment strategy in subjects with atrial fibrillation who undergo percutaneous coronary intervention (PIONEER AF-PCI)
Year: 2014
Type: article
Source: American Heart Journal
Institutions: Beth Israel Deaconess Medical Center, Harvard University, Icahn School of Medicine at Mount Sinai, University of Freiburg, Radboud University Medical Center, Bayer (Germany), Birmingham City Hospital, University of Birmingham, Newark Beth Israel Medical Center, Aarhus University Hospital, Duke Clinical Research Institute, Edinburgh Royal Infirmary, University of Edinburgh
Language: English
Subfield: Cardiology and Cardiovascular Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2017022669
